Accutar Biotechnology

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intel...

  • 1 year ago

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer

CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...

  • 1 year ago

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intel...

  • 1 year ago

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...

  • 2 years ago

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

BROOKLYN, N.Y. - Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on art...

  • 2 years ago

Find us here